NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

In Vitro Activity of Two Ketolides, HMR 3562 and HMR 3787, against Clinical Bacterial Isolates.

FELMINGHAM D, ROBBINS MJ, MATHIAS I, BRYSKIER A; Interscience Conference on Antimicrobial Agents and Chemotherapy.

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1999 Sep 26-29; 39: 351 (abstract no. 2154).

GR Micro Ltd, London, UNITED KINGDOM

The in vitro activity of HMR 3562 and HMR 3787, two new ketolides, and clarithromycin (CLAR) was determined against a wide range of clinical bacterial isolates using the NCCLS agar dilution method. HMR 3562 and HMR 3787 (MIC[90] 0.03-0.06mg/L) were 2-4 times more active than CLAR against erythromycin A (ERY) -susceptible isolates of Staphylococcus spp. Both ketolides retained potent activity against inducibly ERY-resistant strains of Staphylococcus spp but not those exhibiting constitutive MLS[B] resistance. HMR 3787 (MIC[90] 0.008-0.015mg/L) was 2-4 times more active than HMR 3562 and CLAR against ERY[S] isolates of haemolytic Streptococcus spp. and retained good activity (MIC[90] 0.03-0.06mg/L) against strains exhibiting efflux-mediated resistance to CLAR. ERY[S] isolates of S. pneumoniae were very susceptible to HMR 3562 (MIC[90] 0.015mg/L) and HMR 3787 (MIC[90] 0.008mg/L) both ketolides retaining good activity against ERY[R] isolates of this species. Both HMR 3562 and HMR 3787 were highly active against other important respiratory tract pathogens including: Moraxella catarrhalis (MIC[90] 0.06 and 0.06mg/L, respectively), Haemophilus influenzae (2 and 1mg/L), Legionella. pneumophila (0.06 and 0.004mg/L), Chlamydia pneumoniae (0.06 and 0.12mg/L) and Mycoplasma pneumoniae (0.0005 and 0.0005mg/L). Generally, when compared with CLAR, HMR 3562 and HMR 3787 exhibited improved activity against a wide range of gram-positive species and other respiratory tract pathogens, activity being retained against inducibly ERY[R] strains and those exhibiting efflux-mediated resistance.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Chlamydophila pneumoniae
  • Clarithromycin
  • Erythromycin
  • HMR 3562
  • HMR 3787
  • Haemophilus Infections
  • Haemophilus influenzae
  • In Vitro
  • Ketolides
  • Macrolides
  • Microbial Sensitivity Tests
  • Moraxella (Branhamella) catarrhalis
  • Staphylococcus
  • Streptococcus
Other ID:
  • GWAIDS0009124
UI: 102246621

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov